Provided by Tiger Trade Technology Pte. Ltd.

Personalis

7.74
-0.2400-3.01%
Post-market: 7.740.00000.00%16:10 EST
Volume:1.02M
Turnover:8.04M
Market Cap:686.36M
PE:-8.84
High:8.17
Open:8.01
Low:7.68
Close:7.98
52wk High:11.40
52wk Low:2.83
Shares:88.68M
Float Shares:52.59M
Volume Ratio:0.60
T/O Rate:1.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8755
EPS(LYR):-1.3719
ROE:-43.69%
ROA:-20.95%
PB:4.00
PE(LYR):-5.64

Loading ...

BRIEF-Personalis Announces New Publication Applying Ultrasensitive CtDNA Testing

Reuters
·
Yesterday

Personalis Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Outcomes Across Solid Tumors

Reuters
·
Yesterday

Personalis Announces New Publication Applying Ultrasensitive Ctdna Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

THOMSON REUTERS
·
Yesterday

Personalis NeXT Personal Test Shows High Sensitivity for Lung Cancer MRD Detection in Landmark Study

Reuters
·
Dec 11

Personalis Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Dec 03

Morgan Stanley Raises Price Target on Personalis to $11 From $9, Keeps Equalweight Rating

MT Newswires Live
·
Dec 02

Personalis Announces $100M Stock Offering Amendment

TIPRANKS
·
Nov 29

Personalis CFO and COO Aaron Tachibana Reports Disposal of Common Shares

Reuters
·
Nov 29

Personalis (PSNL) Gets a Buy from Lake Street

TIPRANKS
·
Nov 25

BRIEF-Personalis Says CMS Revises Reimbursement Rate For Personal Test For Post-Treatment Surveillance Of Cancers

Reuters
·
Nov 25

Personalis Inc - Effective December 1, Reimbursement Rate for Next Personal Dx Breast Mrd Test Set at $4,266 - SEC Filing

THOMSON REUTERS
·
Nov 25

Personalis Inc - CMS Revises Reimbursement Rate for Next Personal Test for Post-Treatment Surveillance of Cancer - SEC Filing

THOMSON REUTERS
·
Nov 25

Stock Track | Personalis Soars 5.24% After-Hours on Bullish Analyst Ratings and Price Target Hike

Stock Track
·
Nov 12

Stock Track | Personalis Soars 5.24% After-Hours on Positive Analyst Ratings and Price Target Boost

Stock Track
·
Nov 12

Personalis price target raised to $13 from $10 at H.C. Wainwright

TIPRANKS
·
Nov 11

Personalis Is Maintained at Buy by BTIG

Dow Jones
·
Nov 11

Personalis Secures Medicare Coverage for NeXT Personal MRD Test, Positioning for Growth in Underpenetrated $20 Billion Market

TIPRANKS
·
Nov 10

Stock Track | Personalis Skyrockets 20.63% as Medicare Approves Coverage for Breast Cancer MRD Test

Stock Track
·
Nov 10

Stock Track | Personalis Soars 5.34% Pre-market on Medicare Coverage for Breast Cancer Test

Stock Track
·
Nov 10

Stock Track | Personalis Soars 5.34% Pre-Market on Medicare Coverage for Breast Cancer Test

Stock Track
·
Nov 10